

March 17, 2023

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Sub: Approval of the Scheme of Amalgamation by Hon'ble NCLT, Ahmedabad Bench

Ref: Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In furtherance to Company's letters dated February 03, 2020, February 11, 2020 and May 13, 2022 and in terms of Regulation 30 read with Regulation 37 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that Hon'ble National Company Law Tribunal ("NCLT"), Ahmedabad Bench-II has, *vide* its order dated March 17, 2023, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ("Transferee Company") and APL Institute of Clinical Laboratory & Research Private Limited ("Transferor Company"), a wholly owned subsidiary of Transferee Company.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Rajat Kalra

Company Secretary and Legal Head